The global omega-3 market is expected to almost double in value during the next five years, reaching $8.73bn by 2031 from $4.88bn in 2026, according to a new report from MarketsandMarkets.
The market intelligence firm forecasted a 12.3% compound annual growth rate (CAGR), citing growing consumer awareness of omega-3's role in cardiovascular, cognitive and eye health, alongside rising demand for preventive nutrition solutions.
According to the report, marine-derived omega-3s will continue to dominate the sector, accounting for an estimated 93.6% market share in 2026, while docosahexaenoic acid (DHA) is expected to remain the leading omega-3 ingredient thanks to its widespread use in dietary supplements, functional foods and infant nutrition.
MarketsandMarkets also identified infant formula as the fastest-growing application segment, with a projected CAGR of 13.6% through 2031.
Demand is being supported by growing recognition of DHA's role in infant brain and visual development, as well as regulatory requirements in key markets.
In Europe, infant and follow-on formula products must contain specified levels of DHA under EU legislation, helping sustain long-term demand for high-quality omega-3 ingredients.
North America is forecast to remain the largest regional market, accounting for 37% of global sales in 2026, although Europe is expected to retain a significant share thanks to strong consumer awareness, established regulatory frameworks and continued investment in sustainable omega-3 production.
The report noted that clean-label trends and growing interest in plant-based nutrition are also creating opportunities for algal-derived omega-3 ingredients, particularly among vegetarian and flexitarian consumers.
At the same time, ingredient manufacturers are investing in technologies that improve stability, shelf life and formulation flexibility for use in capsules, powders, beverages and fortified foods.
The market remains highly competitive, with major suppliers including dsm-firmenich, BASF, Aker BioMarine, Corbion, Croda International and ADM continuing to expand their omega-3 portfolios across dietary supplements, functional foods and pharmaceutical applications.
The bullish outlook comes as scientific and regulatory interest in DHA continues to grow.
Earlier this year, the European Food Safety Authority (EFSA) reaffirmed a safe supplemental intake level of 1 g/day of DHA, underscoring the ingredient's established role in nutrition while highlighting ongoing research into novel omega-3 sources.
